Celery Seed Extract for Health & Longevity
Evidence Review created on 10/19/2026 using AI4L + evidence-mcp / Gemini 4 Argon
Also known as: Apium graveolens Seed Extract, Apium graveolens Extract, Celery Seed, Celery Extract, CSE, 3-n-Butylphthalide, 3nB
Motivation
Celery seed extract (Apium graveolens seed extract) is a concentrated botanical preparation derived from the dried fruits of the culinary celery plant. Standardized oral extracts concentrate aromatic compounds called phthalides alongside plant flavonoids at levels far exceeding those obtained from eating fresh celery stalks. These compounds are investigated mainly for how they influence blood vessel tone and uric acid production. Health- and longevity-oriented adults have taken an interest in the extract as a non-prescription option investigated in connection with cardiovascular and metabolic aging markers.
Traditional Ayurvedic, Unani, and European herbal systems have used celery seeds for centuries in connection with fluid balance, joint comfort, and digestion. Modern clinical interest grew after researchers isolated the aromatic compound responsible for celery’s scent and began testing standardized seed extracts in human clinical trials focused on blood pressure and metabolic markers.
This review evaluates the human clinical trial data, biological mechanisms, safety profile, drug interactions, dosing protocols, and monitoring markers for oral celery seed extract in the context of health and longevity.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section curates accessible expert overviews, narrative reviews, and primary clinical research examining the pharmacology and clinical applications of celery seed extract.
-
Natural Extracts Lower Blood Pressure - Brandon Dewitte
Reviews how celery seed extract standardized to 85% 3-n-butylphthalide (3nB, a volatile aromatic compound responsible for celery’s scent and vascular activity) relaxes arterial smooth muscle and lowers human blood pressure.
-
Beneficial effects of celery (Apium graveolens) on metabolic syndrome: A review of the existing evidences. - Hedayati et al., 2019
Synthesizes preclinical and clinical mechanisms through which Apium graveolens phytochemicals modulate blood pressure, glucose homeostasis, plasma lipids, and vascular oxidative stress across components of metabolic syndrome.
-
Celery Seed and Related Extracts with Antiarthritic, Antiulcer, and Antimicrobial Activities. - Powanda et al., 2015
Details the phytochemical profile, anti-inflammatory pathways, gastric mucosal protection, and toxicology of standardized Apium graveolens seed extracts developed for joint inflammation and gastrointestinal protection.
-
An Updated Phytopharmacological Review on Medicinal Plant of Arab Region: Apium graveolens Linn. - Al-Asmari et al., 2017
Provides a comprehensive overview of the traditional ethnomedical history, essential oil and flavonoid composition, cardiovascular pharmacology, and preclinical toxicology of Apium graveolens.
-
Effect of Celery Seed (Apium graveolens L.) Administration on the Components of Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion: A Clinical Trial. - Escobedo-Gutiérrez et al., 2026
Reports a 12-week randomized, double-blind, placebo-controlled trial evaluating oral celery seed capsules on blood pressure, serum uric acid, triglycerides, and insulin sensitivity in adults with metabolic syndrome.
Direct searches of the remaining prioritized expert platforms (Rhonda Patrick at FoundMyFitness, Peter Attia, Andrew Huberman, Chris Kresser, and Lifespan.io) returned no dedicated articles, podcast episodes, or clinical commentaries addressing celery seed extract.
Grokipedia
No Grokipedia article on Celery Seed Extract exists as of October 2026.
Examine
-
Summarizes human clinical trials and meta-analytic evidence on Apium graveolens seed preparations, grading blood pressure reduction in hypertensive adults as its primary evidence-backed outcome alongside dosing and safety data.
ConsumerLab
No ConsumerLab article on Celery Seed Extract exists as of October 2026.
Systematic Reviews
This section lists systematic reviews and meta-analyses evaluating the clinical cardiometabolic, neurological, reproductive, and drug-interaction evidence for Apium graveolens and its active constituents.
-
Effects of celery (Apium graveolens) on blood pressure, glycemic and lipid profile in adults: a systematic review and meta-analysis of randomized controlled trials. - Liu et al., 2025
Pools ten randomized controlled trials (RCTs, studies randomly assigning participants to active or control groups), finding reductions in blood pressure, fasting glucose, and triglycerides.
-
Plant-derived therapies in Parkinson’s disease: a systematic review of clinical evidence. - Sukmueng et al., 2026
Evaluates clinical trials of botanical compounds in Parkinson’s disease, including Apium graveolens derived 3nB for motor symptoms, sleep quality, and quality of life.
-
The effect of celery (Apium graveolens L.) on fertility: A systematic review. - Kooti et al., 2017
Assesses sixteen studies demonstrating protective antioxidant effects on spermatogenesis (sperm production) at moderate doses alongside fertility-inhibiting risks with chronic or high-concentration exposure.
-
The most important medicinal plants affecting sperm and testosterone production: a systematic review. - Boroujeni et al., 2022
Reviews experimental evidence on medicinal plants modulating male reproductive hormones, identifying Apium graveolens extracts as enhancers of sperm parameters and testicular antioxidant defenses.
-
Herbs with anti-lipid effects and their interactions with statins as a chemical anti- hyperlipidemia group drugs: A systematic review. - Rouhi-Boroujeni et al., 2015
Examines botanicals in hyperlipidemia (elevated blood fats), noting celery inhibits hepatic triglyceride synthesis while certain herbs reduce statin (cholesterol-lowering drug) absorption.
While Kooti et al., 2017 and Rouhi-Boroujeni et al., 2015 evaluate high-dose reproductive inhibition and herb-statin interactions, no standalone systematic review or meta-analysis exclusively evaluates the clinical adverse-event profile of celery seed extract.
Mechanism of Action
Celery seed extract acts primarily through volatile phthalides—chiefly 3nB (also abbreviated NBP in clinical studies) and sedanolide—alongside flavonoids including apigenin, luteolin, and apiin (Hedayati et al., 2019). In vascular smooth muscle, 3nB blocks L-type voltage-gated calcium channels (pores triggering muscle contraction), reducing calcium influx and arterial tone (Moghadam et al., 2013). Concurrently, 3nB and apigenin upregulate endothelial nitric oxide synthase (eNOS, the vessel-lining enzyme producing vasodilatory nitric oxide) and prostacyclin (PGI2, a vasodilatory, anti-platelet lipid). Competing hypotheses attribute blood-pressure lowering either to direct calcium-channel and nitric-oxide vasodilation or to natriuretic (sodium-excreting) and sympathetic nervous system modulation (Shayani Rad et al., 2022).
Luteolin, apigenin, and chrysoeriol competitively inhibit xanthine oxidase (XO, the liver enzyme converting purines into uric acid) (Gan et al., 2023, authored by supplement manufacturer Nutrilite R&D scientists), suppress nuclear factor kappa B (NF-κB, an inflammatory transcription factor) and cyclooxygenase-2 (COX-2, a prostaglandin-synthesizing enzyme), and activate AMP-activated protein kinase (AMPK, a cellular energy sensor).
In human pharmacokinetics (Diao et al., 2013), oral 3nB reaches peak plasma concentration (Tmax, time to peak blood level) in 0.75 hours, crosses the blood-brain barrier, and has an elimination half-life (t1/2, time for concentration to halve) of 5.33 hours. Hepatic cytochrome P450 3A4 (CYP3A4, primary drug-metabolizing enzyme), cytochrome P450 2E1 (CYP2E1, small-molecule liver enzyme), cytochrome P450 1A2 (CYP1A2, aromatic-metabolizing liver enzyme), and sulfotransferase 1A1 (SULT1A1, sulfate-attaching liver enzyme) metabolize 3nB into conjugates detoxified by glutathione (GSH, cellular antioxidant) before 81.6% urinary excretion (Diao et al., 2014).
Historical Context & Evolution
For over two millennia, dried Apium graveolens seeds were used in Ayurvedic, Unani, Greco-Arabic, and European herbal medicine as a diuretic, carminative (gas-relieving agent), and anti-rheumatic remedy for fluid retention, gouty joint pain, and digestive spasms (Al-Asmari et al., 2017; Powanda et al., 2015). Interest in health optimization began when phytochemists isolated 3nB as the compound responsible for celery’s aroma and vascular relaxation. Preclinical studies in hypertensive rats showed that 3nB-rich seed extracts lowered arterial pressure by 23 to 38 mmHg without affecting normotensive rats (Moghadam et al., 2013). In 2002, Chinese regulators approved synthetic dl-3-n-butylphthalide for ischemic stroke, spurring research into neuroprotection (Tan et al., 2023).
Early human evidence relied on open-label pilot studies, leaving questions about placebo effects. Subsequent double-blind crossover trials in hypertensive adults demonstrated reductions of 11 mmHg in systolic blood pressure (SBP, peak arterial pressure during heartbeats) and 8 mmHg in diastolic blood pressure (DBP, arterial pressure between beats) over 4 weeks at 1,340 mg/day (Shayani Rad et al., 2022). Recent trials confirmed blood-pressure, triglyceride, and uric-acid reductions at 150 mg/day in metabolic syndrome (Escobedo-Gutiérrez et al., 2026), whereas 750 mg/day unstandardized celery powder in overweight type 2 diabetics did not alter blood pressure, fasting plasma glucose (FPG, overnight fasting blood sugar), or lipids (Mohsenpour et al., 2023).
Expected Benefits
High 🟩 🟩 🟩
Blood Pressure Reduction
Oral celery seed supplementation lowers arterial blood pressure in adults with hypertension or metabolic syndrome via L-type calcium channel blockade and eNOS activation. Double-blind RCTs from independent research groups—including Shayani Rad et al. (Shayani Rad et al., 2022) in 52 hypertensive patients taking 1,340 mg/day and Escobedo-Gutiérrez et al. (Escobedo-Gutiérrez et al., 2026) in 28 metabolic syndrome patients taking 150 mg/day—and a 10-RCT meta-analysis (Liu et al., 2025) confirm significant reductions. A trial in normotensive overweight diabetics (Mohsenpour et al., 2023) found no change, indicating benefits require elevated baseline pressure.
Magnitude: Pooled between-group standardized mean difference (SMD, effect size in standard-deviation units) of -1.00 (95% confidence interval [CI, range of plausible true values]: -1.85 to -0.14) for SBP and -0.93 (95% CI: -1.54 to -0.33) for DBP (Liu et al., 2025); in 24-hour ambulatory monitoring, SBP fell from 141.2 ± 5.91 to 130.0 ± 4.38 mmHg and DBP fell from 92.2 ± 5.74 to 84.2 ± 4.87 mmHg in the celery seed group versus no significant change in placebo (p > 0.05; not compared between groups in the abstract) (Shayani Rad et al., 2022).
Medium 🟩 🟩
Serum Uric Acid Reduction
Celery seed supplementation lowers circulating serum uric acid in adults with metabolic dysfunction by inhibiting hepatic XO via luteolin, apigenin, and chrysoeriol (Gan et al., 2023, authored by supplement manufacturer Nutrilite R&D scientists). In a 12-week double-blind RCT in 28 adults with metabolic syndrome (Escobedo-Gutiérrez et al., 2026), 150 mg/day of celery seed significantly reduced serum uric acid from baseline, while placebo showed no change. Because clinical efficacy rests on a single controlled trial, independent replication in hyperuricemia (elevated blood uric acid) is still needed.
Magnitude: Statistically significant between-group reduction compared with placebo (between-group p = 0.001, effect size r = -0.61, where p denotes statistical probability of chance and r denotes rank-biserial correlation; within-group drop from 297.4 ± 53.5 to 261.7 ± 53.5 µmol/L, or -35.7 µmol/L [-0.60 mg/dL], p = 0.009, versus no significant change in placebo) (Escobedo-Gutiérrez et al., 2026).
Anxiety and Depressive Symptom Reduction
Standardized celery seed extract reduces clinical anxiety and depressive symptoms in hypertensive adults, attributed to 3nB modulation of gamma-aminobutyric acid (GABA, the brain’s primary calming neurotransmitter) and cerebral blood flow. In a 4-week double-blind crossover RCT in 50 hypertensive patients (Shayani Rad et al., 2023), 1,340 mg/day significantly lowered Beck Anxiety Inventory (BAI, a 21-item anxiety scale) and Beck Depression Inventory (BDI, a 21-item depression scale) scores versus placebo. Evidence comes from a single research group studying hypertensive patients.
Magnitude: Within-group mean reduction of 6.78 points on the BAI (p < 0.001) and 3.63 points on the BDI (p < 0.01) during 4 weeks of celery seed extract; the available abstract does not report the placebo-step score changes (not compared between groups) (Shayani Rad et al., 2023).
Female Sexual Function Improvement
Oral celery seed supplementation improves sexual desire, arousal, lubrication, and dyspareunia (painful intercourse) in women with sexual dysfunction via nitric-oxide pelvic vasodilation and phytoestrogenic flavonoids. A 6-week double-blind RCT in 80 women with female sexual dysfunction (Hessami et al., 2021) administering 1,500 mg/day (500 mg three times daily) significantly improved total Female Sexual Function Index (FSFI, a 19-item clinical questionnaire) and domain scores versus placebo. Replication in healthy or postmenopausal women is lacking.
Magnitude: Statistically significant increase in total FSFI score and desire, arousal, lubrication (all p < 0.001), and pain reduction (p = 0.033) domains compared with placebo after 6 weeks at 1,500 mg/day; the available abstract reports p-values and direction of improvement without numeric score differences (Hessami et al., 2021).
Low 🟩
Serum Lipid Profile Modulation ⚠️ Conflicted
Celery seed activates AMPK, lowering triglycerides (Liu et al., 2025; Shayani Rad et al., 2022; Escobedo-Gutiérrez et al., 2026). Conversely, Liu et al., 2025 and Mohsenpour et al., 2023 found no effect on total, low-density, or high-density cholesterol. Net reading: supplementation lowers triglycerides without consistently altering cholesterol fractions.
Magnitude: Pooled between-group SMD of -1.18 (95% CI: -1.45 to -0.91) for triglycerides (TG, blood fats) and reduced very-low-density lipoprotein (VLDL, liver triglyceride particles) (Escobedo-Gutiérrez et al., 2026), but non-significant SMDs of -0.33 (95% CI: -1.03 to 0.37) for total cholesterol (TC), -0.73 (95% CI: -1.71 to 0.25) for low-density lipoprotein cholesterol (LDL-C, atherogenic cholesterol), and 1.21 (95% CI: -0.61 to 3.03) for high-density lipoprotein cholesterol (HDL-C, protective cholesterol) (Liu et al., 2025).
Glycemic Control and Insulin Sensitivity ⚠️ Conflicted
Flavonoids stimulate glucose uptake, lowering FPG over 4 weeks (Shayani Rad et al., 2022). However, 12-week RCTs (Escobedo-Gutiérrez et al., 2026; Mohsenpour et al., 2023) and ≥30-day analyses (Liu et al., 2025) found no glycemic effect. Net reading: short-term extracts lower FPG, whereas trials ≥30 days show no benefit.
Magnitude: Pooled between-group SMD of -0.80 (95% CI: -1.58 to -0.01) for FPG overall, dropping to a non-significant SMD of 0.09 (95% CI: -0.20 to 0.39) in trials lasting ≥30 days (Liu et al., 2025).
Osteoarthritis Joint Pain and Cartilage Protection
Celery seed inhibits COX-2 and cartilage-degrading enzymes. A 90-day RCT in 62 knee osteoarthritis patients co-authored by supplement manufacturers Phytoveda and Viridis Biopharma (Vaidya et al., 2025) reduced pain and cartilage turnover. Evidence is indirect because 250 mg celery seed extract was combined with 300 mg Boswellia serrata extract.
Magnitude: Statistically significant reductions in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, validated joint pain and function score), Visual Analog Scale (VAS, 0–10 pain score), and serum/urinary cartilage-degeneration biomarkers compared with both baseline and placebo after 90 days of the combination (250 mg celery seed extract plus 300 mg Boswellia serrata extract); the available abstract reports significant between-group direction without numeric score differences (Vaidya et al., 2025).
Neuroprotection in Parkinson’s and Alzheimer’s Disease
The constituent 3nB protects mitochondrial function and cerebral microcirculation. A 24-week Parkinson’s RCT (Zhou et al., 2019) and a 6-RCT Alzheimer’s meta-analysis (Huang et al., 2026) improved motor and cognitive scores. Evidence is indirect because trials tested 600 mg/day synthetic dl-3-n-butylphthalide rather than botanical extract.
Magnitude: Statistically significant between-group improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III, clinical motor examination score) non-tremor bradykinesia (slowness of movement) and stiffness scores over 24 weeks (Zhou et al., 2019) and pooled Mini-Mental State Examination (MMSE, 30-point cognitive screen) and Montreal Cognitive Assessment (MoCA, 30-point cognitive test) scores across 6 trials (Huang et al., 2026); abstracts report significant direction without pooled point estimates.
Functional Dyspepsia and Dysmenorrhea Relief ⭕️ Not Central to Health & Longevity
Essential oils relax smooth muscle, bearing on acute relief of functional dyspepsia (upper digestive discomfort) and primary dysmenorrhea (menstrual cramps) rather than longevity. Two RCTs improved dyspepsia (Azimi et al., 2017) and dysmenorrhea (Nahid et al., 2009). Evidence is indirect because both tested multi-herb combinations rather than celery seed alone.
Magnitude: Statistically significant between-group reductions in functional dyspepsia symptom severity and frequency compared with placebo and omeprazole after 4 and 8 weeks (Azimi et al., 2017) and in primary dysmenorrhea VAS pain intensity and duration compared with placebo and mefenamic acid over 2–3 menstrual cycles at 1,500 mg/day of the combined herbal extract (p < 0.001); the available abstracts report p-values and between-group direction without numeric score differences (Nahid et al., 2009).
Speculative 🟨
Male Fertility and Spermatogenesis Protection
Moderate doses of hydroalcoholic celery extracts protect rodent testes against oxidative stress and increase sperm count and motility (Kooti et al., 2017; Boroujeni et al., 2022). No controlled human trials exist; evidence is preclinical only.
Gastroprotective and Anti-Helicobacter pylori Activity
Celery seed extracts and luteolin inhibit Helicobacter pylori in vitro and reduce gastric ulcers and colitis (colon inflammation) in rodents (Powanda et al., 2015; Minaiyan et al., 2021). No human trials exist; basis is preclinical.
Benefit-Modifying Factors
- Genetic polymorphisms: Variants in hepatic CYP3A4, CYP2E1, CYP1A2, and SULT1A1 alter the oxidation and sulfation rate of 3nB (Diao et al., 2013; Diao et al., 2014). Rapid metabolizers clear active phthalides faster, potentially requiring split dosing to sustain 24-hour vascular calcium-channel blockade.
- Baseline biomarker levels: Antihypertensive and urate-lowering magnitudes scale with baseline elevation. Hypertensive adults (SBP ~141 mmHg) experienced ~11 mmHg SBP drops (Shayani Rad et al., 2022), whereas normotensive overweight diabetics showed no blood-pressure change (Mohsenpour et al., 2023).
- Sex-based differences: Meta-regression links sex to DBP response (Liu et al., 2025), with exploratory data showing larger blood-pressure drops in women and triglyceride drops in men (Escobedo-Gutiérrez et al., 2026). Female sexual function improved clinically (Hessami et al., 2021); male fertility remains preclinical.
- Pre-existing health conditions: Adults with hypertension or metabolic syndrome exhibit consistent reductions in blood pressure, triglycerides, and uric acid (Escobedo-Gutiérrez et al., 2026), whereas normotensive type 2 diabetics show minimal glycemic or lipid response (Mohsenpour et al., 2023).
- Age-related considerations: Older adults with age-related arterial stiffening and reduced endothelial nitric oxide bioavailability match the primary mechanism of 3nB and apigenin, with clinical efficacy demonstrated across cohorts spanning 30 to 70 years of age (Shayani Rad et al., 2022).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: human randomized controlled trials from independent research groups have not demonstrated any statistically significant excess clinical adverse events or validated biomarker harms compared with placebo.
Medium 🟥 🟥
No risk reaches Medium: no single controlled human trial or comparative observational cohort has established a statistically significant adverse event attributable to oral celery seed extract alone.
Low 🟥
Mild Gastrointestinal and Dermatologic Discomfort ⚠️ Conflicted
Oral celery seed or 3nB occasionally coincides with mild nausea, abdominal discomfort, or rash (Tan et al., 2023). However, RCTs (Shayani Rad et al., 2022; Escobedo-Gutiérrez et al., 2026) and Liu et al., 2025 found no excess adverse events over placebo. Net reading: mild symptoms match placebo rates.
Magnitude: No statistically significant between-group difference in adverse-event incidence versus placebo across 4-to-12-week RCTs (p > 0.05) (Shayani Rad et al., 2022; Liu et al., 2025), with 12-week rates of mild diarrhea (7.1%) and abdominal distension (7.1%) in the celery seed group versus headache (21.4%) and 7.1% each of nausea, diarrhea, abdominal distension, and constipation in placebo (Escobedo-Gutiérrez et al., 2026); for 600 mg/day synthetic NBP over 24 weeks, a scoping review reported a 7% adverse-event rate without reporting the comparison-group rate (Tan et al., 2023).
Severe Allergic Cross-Reactivity
Heat-stable Apium graveolens proteins trigger immunoglobulin E (IgE, allergy-antibody) reactions up to anaphylaxis (severe allergic shock) (Lüttkopf et al., 2000; Silverstein et al., 1986). Controlled food challenges confirm reactivity (Ballmer-Weber et al., 2000; Dölle et al., 2018), though evidence is indirect from whole celery rather than seed extract.
Magnitude: Among 32 adults with suspected celery allergy (sensitized to Api g 1 and Api g 4 proteins) undergoing double-blind, placebo-controlled food challenge (DBPCFC, the gold-standard clinical allergy test), 22 of 32 experienced confirmed allergic reactions to celery versus 2 of 32 reacting to placebo (Ballmer-Weber et al., 2000; Lüttkopf et al., 2000).
Furanocoumarin-Induced Phototoxicity
Apium graveolens contains furanocoumarins (psoralens, light-reactive compounds) that bind skin DNA under ultraviolet A (UVA, long-wave ultraviolet light), causing phytophotodermatitis (blistering skin inflammation) (Pate et al., 2025). Human evidence is indirect and uncontrolled, based on phototoxic reactions to handled or ingested whole celery (MacLaurin et al., 2026).
Magnitude: Not quantified in available studies. No controlled trial has measured phototoxicity from celery seed extract; human reports are limited to a grocery-worker outbreak (phytophotodermatitis in 6/8 [75%] sunbed users versus 13/39 [33%] non-users handling psoralen-rich celery) and 15 sunbed phototoxic reactions across celery, parsnip, and lime juice combined (14 contact, 1 oral ingestion of ~450 g celery; no control group) (MacLaurin et al., 2026).
Speculative 🟨
High-Dose Spermatogenesis Inhibition
While moderate doses protect rodent testes, chronic high-concentration Apium graveolens extracts arrest spermatogenesis and shrink seminiferous tubules in rats (Kooti et al., 2017). No controlled human data exist; basis is animal toxicology only.
Reactive Metabolite Hepatotoxicity
Hepatic SULT1A1 converts 3-hydroxy-NBP into reactive metabolites detoxified by GSH, and synthetic NBP occasionally raises transaminases (Diao et al., 2014; Huang et al., 2026). Botanical extract lowered human liver enzymes (Shayani Rad et al., 2022).
Risk-Modifying Factors
- Genetic polymorphisms: High-activity SULT1A1 or impaired CYP3A4 and CYP2E1 variants increase reactive 3-hydroxy-NBP sulfate formation (Diao et al., 2014), while cytochrome P450 2D6 (CYP2D6, a drug-metabolizing liver enzyme) poor-metabolizer status amplifies herb-drug interactions (Nguyen et al., 2014).
- Baseline biomarker levels: Low baseline blood pressure (<100/60 mmHg) increases susceptibility to symptomatic hypotension, whereas depleted intracellular glutathione or elevated baseline alanine aminotransferase (ALT, a liver injury enzyme) increases susceptibility to 3nB metabolite stress (Diao et al., 2014).
- Sex-based differences: In women, high doses of apiol and volatile oils stimulate uterine contractions during pregnancy (Al-Asmari et al., 2017). In men, preclinical models indicate dose-dependent testicular sensitivity at high chronic concentrations (Kooti et al., 2017).
- Pre-existing health conditions: Individuals with birch or mugwort pollen sensitization carry high cross-reactive IgE risk via celery-birch-mugwort-spice syndrome (Ballmer-Weber et al., 2000). Active renal inflammation or hepatic impairment slows clearance of renal-excreted 3nB metabolites (Diao et al., 2013).
- Age-related considerations: Older adults face a higher prevalence of polypharmacy (concurrent use of multiple medications) and baroreceptor blunting, increasing the risk of orthostatic hypotension (a sudden blood-pressure drop upon standing) when combining celery seed extract with antihypertensives.
Key Interactions & Contraindications
- Antihypertensives — calcium channel blockers (CCBs, vessel-relaxing drugs; amlodipine), angiotensin-converting enzyme (ACE) inhibitors (angiotensin-blocking drugs; lisinopril), angiotensin II receptor blockers (ARBs, receptor blockers; losartan), and diuretics (hydrochlorothiazide): Monitor (theoretical). Additive vasodilation can cause hypotension; mitigation involves daily blood-pressure tracking and physician-supervised dose adjustment.
- CYP3A4, CYP2D6, and cytochrome P450 2A6 (CYP2A6, nicotine-metabolizing enzyme) substrates (atorvastatin, metoprolol, nicotine): Caution (theoretical). Extracts inhibit CYP2D6/3A4/2A6 (Nguyen et al., 2014; Deng et al., 2016) and statin uptake (Rouhi-Boroujeni et al., 2015), though Powanda et al., 2015 saw no effect; dose spacing mitigates overlap.
- Prescription anticoagulants and over-the-counter antiplatelets (warfarin, clopidogrel, apixaban, aspirin, ibuprofen, naproxen): Caution (theoretical). Coumarins inhibit platelets (Al-Asmari et al., 2017), though extract reduced nonsteroidal anti-inflammatory drug (NSAID, painkiller) gastric damage (Powanda et al., 2015). International normalized ratio (INR, clotting) tracking and pre-surgical pause mitigate bleeding.
- Over-the-counter analgesics and sedatives (acetaminophen/paracetamol, diphenhydramine, doxylamine, phenobarbital): Caution (theoretical). Preclinical studies show Apium graveolens decreases hepatic cytochrome P450 content and prolongs paracetamol analgesia and barbiturate sedation (Jakovljevic et al., 2002). Avoiding high-dose co-administration prevents excess sedation or delayed clearance.
- Prescription photosensitizing medications and thyroid hormone (doxycycline, ciprofloxacin, hydrochlorothiazide, levothyroxine): Monitor (theoretical). Dietary furanocoumarins can compound drug-induced UVA photosensitivity (MacLaurin et al., 2026), and high-flavonoid botanicals can alter intestinal levothyroxine absorption. Mitigation includes 4-hour levothyroxine separation and UVA sun protection.
- Supplements with hypotensive or antiplatelet activity (aged garlic extract, hibiscus, magnesium, coenzyme Q10, L-citrulline, omega-3 fish oil, Ginkgo biloba): Monitor (theoretical). Co-administration produces additive reductions in arterial pressure or platelet aggregation. Staggered introduction while tracking seated and standing blood pressure mitigates hypotension.
- Phototherapy and ultraviolet tanning interventions (UVA tanning beds, psoralen-UVA photochemotherapy): Avoid (theoretical). Oral or topical celery furanocoumarins combined with artificial UVA exposure have triggered severe phototoxic burns in human case series (MacLaurin et al., 2026). Avoiding artificial UV tanning during supplementation prevents phototoxicity.
Populations who should avoid Celery Seed Extract:
- Individuals with documented allergy to celery, celeriac, carrot (Apiaceae family), birch pollen, or mugwort pollen: Absolute contraindication due to high rates (22 of 32 in DBPCFC) of cross-reactive IgE-mediated reactions and potential anaphylaxis (Ballmer-Weber et al., 2000).
- Pregnant or breastfeeding women: Avoid based on clinical trial exclusion criteria (Shayani Rad et al., 2022; Escobedo-Gutiérrez et al., 2026) and uterine-stimulating effects of apiol and volatile oils (Al-Asmari et al., 2017).
- Individuals with uncontrolled renal disease (serum creatinine above the upper limit of normal) or active kidney inflammation: Avoid based on clinical trial exclusion criteria (NCT06084585; Escobedo-Gutiérrez et al., 2026) and predominantly renal (81.6%) metabolite excretion (Diao et al., 2013).
- Individuals with hepatic disease or elevated liver transaminases (ALT or aspartate aminotransferase [AST, liver enzyme] above the upper limit of normal): Avoid per trial exclusion criteria (NCT06084585; Escobedo-Gutiérrez et al., 2026) and hepatic CYP3A4/SULT1A1 bioactivation (Diao et al., 2014).
- Patients scheduled for upcoming elective surgical procedures: Avoid (theoretical) due to antiplatelet and vasodilatory effects of coumarins, apigenin, and 3nB (Al-Asmari et al., 2017).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Allergy cross-reactivity screening: Screening for prior oral itching or swelling from raw celery, carrots, spices, birch pollen, or mugwort pollen before first use (Ballmer-Weber et al., 2000) prevents IgE-mediated allergic reactions and anaphylaxis.
- Low starting dose with blood-pressure titration: Initiating at 75–150 mg once daily with food for 7–14 days before escalating, and pausing supplementation if seated blood pressure falls below 90/60 mmHg, prevents symptomatic or orthostatic hypotension.
- Meal-paired split dosing: Administering capsules with morning and evening meals rather than on an empty stomach and splitting doses above 150 mg/day into two or three intakes (Shayani Rad et al., 2022) minimizes mild gastrointestinal discomfort and nausea.
- Standardized low-furanocoumarin seed extracts and UV protection: Using encapsulated seed extracts standardized for 3nB rather than raw celery juice, avoiding UVA tanning beds (MacLaurin et al., 2026), and applying broad-spectrum UVA sunscreen during prolonged sun exposure prevents phytophotodermatitis.
- Hepatic enzyme and glutathione support: Avoiding supratherapeutic dosing, maintaining dietary sulfur amino acids to support GSH detoxification (Diao et al., 2014), and discontinuing use if ALT or AST exceeds the upper limit of normal (NCT06084585) mitigates hepatotoxicity risk.
- Fertility washout in men attempting conception: Capping intake at 150 mg/day or discontinuing supplementation 70–90 days (one spermatogenic cycle) before conception attempts avoids speculative high-dose spermatogenesis inhibition (Kooti et al., 2017).
Therapeutic Protocol
Parameters below without a citation (such as timing, titration steps, and splitting schedules) reflect common clinical practice.
- Standardized high-potency vascular protocol: 1,340 mg/day of celery seed extract standardized to 85% 3nB (taken as 670 mg twice daily in capsules), the regimen demonstrated by Shayani Rad et al., 2022 to lower 24-hour ambulatory blood pressure, lipids, and anxiety.
- Integrative standardized low-dose protocol: 150 mg/day (75 mg twice daily) standardized to 85% phthalides, popularized by Brandon Dewitte at Life Extension and validated in metabolic syndrome by Escobedo-Gutiérrez et al., 2026 for blood pressure, triglycerides, and uric acid.
- Whole-seed powder protocol: 1,500 mg/day of encapsulated celery seed powder divided into 500 mg three times daily, the regimen used in female sexual dysfunction by Hessami et al., 2021 and primary dysmenorrhea by Nahid et al., 2009.
- Human elimination half-life: Oral 3nB reaches peak plasma concentrations at 0.75 hours and has a human terminal elimination half-life of approximately 5.33 hours, with rapid hepatic oxidation and 81.6% renal excretion within 48 hours (Diao et al., 2013).
- Single versus split dosing: Because of the 5.33-hour half-life of 3nB (Diao et al., 2013), dividing the daily dose into two intakes spaced 12 hours apart (or three spaced 8 hours apart) maintains steadier vascular calcium-channel blockade than once-daily dosing.
- Best time of day: Administration with breakfast and dinner allows dietary lipids to enhance absorption of lipophilic phthalides, while morning and evening coverage blunts both the morning blood-pressure surge and nocturnal non-dipping (Shayani Rad et al., 2022).
- Genetic polymorphisms: Individuals with known slow CYP3A4 or CYP2D6 metabolizer genotypes or high-activity SULT1A1 variants (Diao et al., 2014; Nguyen et al., 2014) are better matched to the 150 mg/day regimen rather than 1,340 mg/day.
- Sex-based protocol considerations: Both sexes use 150–1,340 mg/day for cardiometabolic goals (Liu et al., 2025); women targeting sexual function use 500 mg three times daily (Hessami et al., 2021), while men seeking fertility avoid high-dose regimens (Kooti et al., 2017).
- Age-related considerations: Protocols for adults over 65 typically initiate at 75 mg once daily for 1 week before advancing to 75 mg twice daily (150 mg/day) while tracking standing blood pressure to avoid orthostatic dizziness.
- Baseline biomarker considerations: Adults with overt hypertension (~141/92 mmHg) match the 1,340 mg/day regimen (Shayani Rad et al., 2022), whereas metabolic syndrome patients with blood pressure <140/90 mmHg respond to 150 mg/day (Escobedo-Gutiérrez et al., 2026).
- Pre-existing health conditions: In individuals on concurrent antihypertensive or CYP3A4/CYP2D6-metabolized medications, protocols typically use the 150 mg/day regimen, separate administration by 2–4 hours, and adjust prescription doses only under medical supervision.
Discontinuation & Cycling
- Treatment duration (short-term versus ongoing): Controlled human trials have evaluated continuous administration for 4 to 12 weeks (Shayani Rad et al., 2022; Escobedo-Gutiérrez et al., 2026); safety and efficacy of uninterrupted multi-year supplementation have not been established in long-term RCTs.
- Withdrawal and rebound effects: No acute withdrawal syndrome or rebound hypertension above pre-treatment baseline was observed during the 4-week washout phase of the crossover trial by Shayani Rad et al., 2022, though blood pressure gradually returns toward baseline after stopping.
- Tapering-off protocol: When discontinuing high-dose regimens (1,340 mg/day), stepping down to 670 mg/day (or 150 mg/day) for 7–14 days while monitoring home blood pressure allows smooth vascular adjustment and timely recalibration of any concurrent antihypertensive therapy.
- Cycling schedule: A schedule of 8–12 weeks on followed by a 2–4 week washout is commonly used to assess whether lifestyle changes sustain blood-pressure and uric-acid targets and to avoid chronic testicular or hepatic enzyme exposure (Kooti et al., 2017).
Sourcing and Quality
- Phytochemical standardization: Clinical-grade extracts are standardized to 85% total phthalides (3nB and sedanolide) verified by gas chromatography-mass spectrometry (GC-MS, an analytical method for volatile compounds) or flavonoid glycosides verified by high-performance liquid chromatography (HPLC, an analytical method for non-volatile compounds) (Shayani Rad et al., 2022).
- Plant part and extraction method: Effective formulations specify Apium graveolens seed (fruit) extract obtained via supercritical carbon dioxide or hydroalcoholic extraction rather than unstandardized whole-stalk powder, which failed to improve blood pressure or lipids in Mohsenpour et al., 2023.
- Third-party purity and contaminant testing: High-quality supplements are produced in Current Good Manufacturing Practice (cGMP, federal manufacturing quality standards) facilities with batch certificates of analysis from United States Pharmacopeia (USP) or National Sanitation Foundation (NSF) laboratories testing for heavy metals, residual solvents, and pesticides.
- Established commercial formulations: Brands offering standardized 75 mg or 150 mg celery seed extract capsules (standardized to 85% 3nB) include Natural Factors (Celery Seed Extract 75 mg, 85% 3nB), Life Extension, and Solaray.
Practical Considerations
- Time to effect: Blood-pressure, glucose, and anxiety reductions appear within 4 weeks (Shayani Rad et al., 2022; Shayani Rad et al., 2023), female sexual function improvements by 6 weeks (Hessami et al., 2021), and uric-acid and triglyceride reductions by 12 weeks (Escobedo-Gutiérrez et al., 2026).
- Common pitfalls: Substituting culinary celery juice or unstandardized leaf/stalk powders for standardized seed extract, expecting LDL-C reductions, or adding high-dose extract to prescription antihypertensives without home blood-pressure monitoring are the most frequent implementation errors.
- Regulatory status: Celery seed extract is sold over the counter as a dietary supplement in the United States and as a registered herbal medicine in Australia (Powanda et al., 2015), whereas synthetic dl-3-n-butylphthalide is a prescription stroke medication in China (Tan et al., 2023).
- Cost and accessibility: Standardized celery seed extract is widely accessible online and in pharmacies at low cost, typically ranging from $10 to $25 per month for a 150 mg/day to 1,340 mg/day regimen.
Interaction with Foundational Habits
- Sleep: Potentiating interaction. Celery seed extract does not disrupt sleep; 3nB improved Pittsburgh Sleep Quality Index (PSQI, a sleep questionnaire) scores (Zhou et al., 2019) and lowered nocturnal blood pressure and anxiety (Shayani Rad et al., 2022; Shayani Rad et al., 2023) via GABAergic signaling. Evening doses are taken with dinner 3–4 hours pre-bed.
- Nutrition: Potentiating interaction. Pairing with a low-purine or Dietary Approaches to Stop Hypertension (DASH, a potassium-rich blood-pressure-lowering diet) eating pattern additively lowers uric acid and blood pressure (Escobedo-Gutiérrez et al., 2026). Taking capsules with fat-containing meals aids lipophilic phthalide absorption, while limiting furanocoumarin-rich foods (grapefruit, parsnip) reduces phototoxicity risk.
- Exercise: Indirect interaction; requires caution in sensitized individuals. No evidence indicates that supplementation blunts muscle hypertrophy or adaptations to Zone 2 training (steady aerobic exercise) or high-intensity interval training (HIIT, alternating maximal efforts with recovery). However, vigorous exercise within 2–4 hours of ingestion can trigger celery-dependent exercise-induced anaphylaxis in sensitized individuals (Silverstein et al., 1986).
- Stress management: Potentiating interaction. Standardized celery seed extract (1,340 mg/day) lowered clinical anxiety (BAI by 6.78 points) and depression (BDI by 3.63 points) while blunting sympathetic vascular tone in hypertensive adults (Shayani Rad et al., 2023), complementing breathwork, mindfulness, and heart-rate-variability training to attenuate stress-induced blood-pressure spikes.
Monitoring Protocol & Defining Success
Before initiating celery seed extract, baseline evaluation typically consists of a 7-day home seated and standing blood-pressure log (or 24-hour ambulatory blood-pressure monitor) alongside a fasting morning venous blood draw measuring serum uric acid, fasting triglycerides, liver transaminases (ALT and AST), serum creatinine, and blood urea nitrogen (BUN, a nitrogenous waste product filtered by the kidneys) (Shayani Rad et al., 2022; Escobedo-Gutiérrez et al., 2026). Ongoing monitoring protocols record home seated and standing blood pressure daily during the first 2 weeks and weekly thereafter, and repeat the fasting laboratory panel at 4 weeks, at 12 weeks, and every 6 months during continued supplementation to verify efficacy and hepatic or renal safety.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Seated or 24-hour ambulatory blood pressure (SBP / DBP) | No established target; track reduction from the individual’s own baseline | Marker the intervention is expected to change (efficacy) and safety check against hypotension (Shayani Rad et al., 2022) | Measured seated after 5 minutes of rest and 1–3 minutes after standing; protocols pause use if seated blood pressure drops below 90/60 mmHg. |
| Serum uric acid | 3.5–7.2 mg/dL (208–428 µmol/L) in men; 2.6–6.0 mg/dL (155–357 µmol/L) in women (standard reference range) | Marker the intervention is expected to change via XO inhibition (Escobedo-Gutiérrez et al., 2026) | Drawn fasting in the morning; clinical trial showed a mean reduction of 35.7 µmol/L (0.60 mg/dL) at 12 weeks. |
| Fasting serum triglycerides (TG) | No established target; track reduction from the individual’s own baseline | Marker the intervention is expected to change (Liu et al., 2025; Escobedo-Gutiérrez et al., 2026) | Requires a 10–12 hour overnight fast and alcohol avoidance for 24 hours before the draw. |
| Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) | ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) | Safety check for reactive 3nB sulfate metabolite stress (Diao et al., 2014) and marker of hepatic response (Shayani Rad et al., 2022) | Drawn fasting before heavy exercise; protocols discontinue supplementation if ALT or AST exceeds the upper limit of normal (NCT06084585). |
| Serum creatinine and blood urea nitrogen (BUN) | Creatinine: 0.6–1.3 mg/dL; BUN: 7–20 mg/dL (standard reference range) | Safety check for renal clearance of 3nB metabolites (Diao et al., 2013) and marker improved in hypertensive trials (Shayani Rad et al., 2022) | Paired with estimated glomerular filtration rate (eGFR, a blood calculation of kidney filtration rate) under consistent hydration. |
- Orthostatic tolerance and dizziness: Tracking lightheadedness upon standing during the first 14 days detects excessive vasodilation early.
- Perceived anxiety and mood stability: Subjective calmness or repeated BAI and BDI questionnaires at baseline and week 4 assess mood response (Shayani Rad et al., 2023).
- Joint comfort and morning stiffness: For individuals with uric-acid elevation or osteoarthritis, daily joint discomfort logs on a 0–10 scale over 12 weeks track symptom response (Vaidya et al., 2025).
- Oral, skin, and digestive tolerance: Observing for oral itching, rash after sun exposure, or upper abdominal discomfort after doses identifies intolerance early.
Emerging Research
- Multiple system atrophy (a rare neurodegenerative disorder) neuroprotection trial (NCT07518810): Recruiting Phase 2/3 randomized, double-blind trial (ENMSA, N=150) evaluating 600 mg/day oral butylphthalide capsules over 6 months (12-month follow-up) on main symptom control. A positive result would strengthen 3nB neuroprotection claims, whereas a null result would weaken claims that phthalides slow neurodegeneration.
- Minor acute ischemic stroke recovery trial (NCT07230587): Upcoming Phase 3 randomized trial (BLESS, N=1,200, Not Yet Recruiting) testing 600 mg/day oral butylphthalide capsules over 12 months on a composite of mortality, stroke recurrence, disability, new infarcts, and cognition. A positive outcome would reinforce cerebrovascular benefits, while a null outcome would limit its value.
- Completed metabolic syndrome trial (NCT06061926): Passed its December 2025 completion date (Phase 2, N=28; registry status still listed as Recruiting with no results posted, but published in Escobedo-Gutiérrez et al., 2026), demonstrating reduced SBP, DBP, triglycerides, VLDL, and uric acid at 150 mg/day without altering insulin sensitivity or glucose.
- Unpublished hyperuricemia and osteoarthritis trials (NCT06084585; NCT00577330): Both passed their registered completion dates with status Unknown and no results posted: NCT06084585 (passed March 2024, N=180, multi-herb uric-acid formula containing celery seed) and NCT00577330 (passed January 2008, N=110, Phase 3 trial of Myalgesin—celery seed, Boswellia serrata, and Phellodendron bark extracts—versus acetaminophen in knee osteoarthritis).
- Duration-dependent glycemic attenuation and human fertility safety: Future research aims to resolve why glycemic reductions disappear in trials lasting 30 days or longer (Liu et al., 2025; Mohsenpour et al., 2023) and whether the dual protective versus inhibitory effects on male spermatogenesis observed in rodents (Kooti et al., 2017) occur in humans.
Conclusion
Celery seed extract is a concentrated botanical preparation whose primary active compounds—aromatic phthalides and plant flavonoids—relax arterial smooth muscle, increase blood-vessel nitric oxide, and inhibit the liver enzyme that produces uric acid. For health- and longevity-oriented adults, the strongest human clinical evidence supports blood pressure reduction in individuals with elevated baseline blood pressure, replicated across independent randomized controlled trials and a meta-analysis. Moderate evidence from individual controlled trials supports reductions in blood uric acid and anxiety or depressive symptoms, as well as improvements in female sexual function.
Evidence for broader metabolic and neurological goals is more uncertain. While blood triglycerides consistently decline in adults with metabolic dysfunction, total, low-density, and high-density cholesterol show no consistent improvement, and blood sugar reductions seen in shorter studies disappear in longer trials. Claims for joint pain relief rely on a trial that combined celery seed extract with Boswellia serrata and was co-authored by employees of the supplement manufacturers, just as laboratory uric-acid enzyme research was conducted by supplement company scientists, representing direct commercial conflicts of interest. Neurological findings in Parkinson’s and Alzheimer’s disease derive from high-dose isolated synthetic phthalide rather than whole botanical seed extract.
Oral celery seed extract is well tolerated in short-term clinical trials, with adverse event rates matching placebo, though severe allergic reactions in pollen- or celery-sensitized individuals, sunlight-triggered skin reactions, potential liver-enzyme drug interactions, and rodent high-dose male fertility concerns remain key considerations.